226 related articles for article (PubMed ID: 27038323)
21. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
23. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
24. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.
Guariento S; Bruno O; Fossa P; Cichero E
Mol Divers; 2016 Feb; 20(1):77-92. PubMed ID: 26290462
[TBL] [Abstract][Full Text] [Related]
25. Discovery of triazines as selective PDE4B versus PDE4D inhibitors.
Hagen TJ; Mo X; Burgin AB; Fox D; Zhang Z; Gurney ME
Bioorg Med Chem Lett; 2014 Aug; 24(16):4031-4. PubMed ID: 24998378
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
27. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice.
Guo J; Lin P; Zhao X; Zhang J; Wei X; Wang Q; Wang C
Neuroscience; 2014 Mar; 263():1-14. PubMed ID: 24434771
[TBL] [Abstract][Full Text] [Related]
28. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP
ACS Chem Neurosci; 2017 Jan; 8(1):135-146. PubMed ID: 27690383
[TBL] [Abstract][Full Text] [Related]
29. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.
Zhang HT; Huang Y; Jin SL; Frith SA; Suvarna N; Conti M; O'Donnell JM
Neuropsychopharmacology; 2002 Oct; 27(4):587-95. PubMed ID: 12377395
[TBL] [Abstract][Full Text] [Related]
30. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
31. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase 4 conformers: preparation of recombinant enzymes and assay for inhibitors.
Bardelle C; Smales C; Ito M; Nomoto K; Wong EY; Kato H; Saeki T; Staddon JM
Anal Biochem; 1999 Nov; 275(2):148-55. PubMed ID: 10552898
[TBL] [Abstract][Full Text] [Related]
33. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.
Robichaud A; Stamatiou PB; Jin SL; Lachance N; MacDonald D; Laliberté F; Liu S; Huang Z; Conti M; Chan CC
J Clin Invest; 2002 Oct; 110(7):1045-52. PubMed ID: 12370283
[TBL] [Abstract][Full Text] [Related]
34. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
[TBL] [Abstract][Full Text] [Related]
35. Uterus-relaxing effect of β2-agonists in combination with phosphodiesterase inhibitors: studies on pregnant rat in vivo and on pregnant human myometrium in vitro.
Verli J; Klukovits A; Kormányos Z; Hajagos-Tóth J; Ducza E; Seres AB; Falkay G; Gáspár R
J Obstet Gynaecol Res; 2013 Jan; 39(1):31-9. PubMed ID: 22765375
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
37. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
[TBL] [Abstract][Full Text] [Related]
39. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
Gurney ME; D'Amato EC; Burgin AB
Neurotherapeutics; 2015 Jan; 12(1):49-56. PubMed ID: 25371167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
